A recently published article in Nature Communications describes 173 patients diagnosed with glioblastoma who received a fully personalized neoantigen-based peptide vaccination in addition to their treatment regimen. The data show that the immune-based personalized approach is feasible in a clinical setting and, above all, well-tolerated. Patients who develop an immune response against several neoantigens have a significant survival benefit compared to those who do not show an immune response. This benefit is particularly strong compared to patients who are treated with standard radio- and chemotherapy. The data will now be reviewed as part of a controlled authorization study. Fortunately, many patients are alive and grateful that the data is now available to the scientific community. The hope is that one day all those affected will have access to individualized immunotherapies. This data is certainly an important step in this direction.
